arrow
R

Roberto Álvarez-Lafuente

Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos
H指数:28
被引数:2,675

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Viral immune profiles in multiple sclerosis and HIV co-infection providing insights into antiretroviral treatment-associated immuno-remodeling

多发性硬化与HIV合并感染中的病毒免疫特征,为抗逆转录病毒治疗相关的免疫重塑提供见解

2026-10-090
OAAI
Virus-specific effects of disease-modifying therapies on herpesvirus antibody titers in multiple sclerosis

疾病修正疗法对多发性硬化症患者疱疹病毒抗体滴度的病毒特异性影响

2026-10-050
OA
Serum sTREM2 Levels and Disability Progression in Patients With Primary Progressive Multiple Sclerosis

原发性进行性多发性硬化患者的血清sTREM2水平和残疾进展

2026-01-300
OAAI
Bacterial Metabolites in the Plasma of Type 1 Diabetes Patients: Acetate Levels Are Elevated and Correlate with Glycated Haemoglobin and Para-Cresol Is Associated with Liver Disturbances and Hypertension
2026-01-190
OAAI
Identification of cellular factors associated with inflammation and neurodegeneration in multiple sclerosis

鉴定与炎症和神经退行性变相关的多发性硬化细胞因子

2025-08-070
OA
Short-chain fatty acids in multiple sclerosis: Associated with disability, number of T2 lesions, and inflammatory profile

多发性硬化症中的短链脂肪酸: 与残疾,T2病变数量和炎症状况相关

2025-03-010
OAAI
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis
BRAIN
IF11.7
2024-08-052
PRE
Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis
2024-07-011
OAAI
A two-years real-word study with fingolimod: early predictors of efficacy and an association between EBNA-1 IgG titers and multiple sclerosis progression

fingolimod的一项为期两年的实时研究: 疗效的早期预测指标以及EBNA-1 IgG滴度与多发性硬化进展之间的关联

2024-06-070
OAAI
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

血清生物标志物水平预测原发性进行性多发性硬化患者的残疾进展

2023-11-086
PRE
Teriflunomide and Epstein-Barr virus in a Spanish multiple sclerosis cohort: in vivo antiviral activity and clinical response
2023-09-293
OAAI
microRNA Expression and Its Association With Disability and Brain Atrophy in Multiple Sclerosis Patients Treated With Glatiramer Acetate

醋酸格拉替雷治疗多发性硬化患者的microRNA表达及其与残疾和脑萎缩的关系

2022-06-145
OAAI
Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta Treatment
2021-12-167
OAAI